65 active not recruiting. 65 Phase 2, 25 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 65 | Active not recruiting 65 |
| Phase 1 | 25 | Active not recruiting 25 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Management of Iron Deficiency Anemia in Hemodialysis Patients Lactoferrin, IV iron sucrose - Iron Deficiency Anemia (IDA), ESRD (End Stage Renal Disease) | Phase 2 | Active not recruiting | Beni-Suef University | 108 | 2025-11-02 | 2026-10-30 |
| To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII. Mitapivat - Anemia | Phase 2 | Active not recruiting | University Health Network, Toronto | 9 | 2025-10-20 | 2026-10-15 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Azacitidine (AZA) Days 1 - 5, Selinexor - Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Active not recruiting | Liping Dou | 58 | 2025-05-01 | 2026-08-21 |
| A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) Tebapivat, Tebapivat Matched Placebo - Sickle Cell Disease | Phase 2 | Active not recruiting | Agios Pharmaceuticals, Inc. | 59 | 2025-05-01 | 2026-10-28 |
| ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia ALS20 - Beta-Thalassemia | Phase 1 / Phase 2 | Active not recruiting | Children's Hospital of Philadelphia | 12 | 2025-04-14 | 2026-10-29 |
| A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients NTQ5082 100mg qd, NTQ5082 200mg qd - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Active not recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 24 | 2025-01-23 | 2025-09-23 |
| Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients. LP-005 Injection - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Active not recruiting | Longbio Pharma | 30 | 2024-11-14 | 2026-01-16 |
| A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body REGN7999, Placebo - Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 19 | 2024-09-30 | 2026-07-01 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia Vebeglogene autotemcel - Beta-Thalassemia | Phase 1 / Phase 2 | Active not recruiting | Lantu Biopharma | 6 | 2024-05-11 | 2026-06-15 |
| LEARNER- Low dosE AspiRiN prEterm tRial (Angola) Aspirin 100mg - Sickle Cell Disease, Pregnancy Related | Phase 1 / Phase 2 | Active not recruiting | Instituto Nacional de Investigacao em Saude, Angola | 450 | 2024-03-16 | 2026-07-06 |
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure Ruxolitinib - Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 13 | 2024-02-20 | 2026-10-14 |
| Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria OMS906 study drug - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Active not recruiting | Omeros Corporation | 25 | 2024-02-19 | 2026-07-16 |
| Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria HRS-5965 tablets, HRS-5965 Capsules - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Active not recruiting | Chengdu Suncadia Medicine Co., Ltd. | 132 | 2024-02-06 | 2025-12-24 |
| Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function Briquilimab, Filgrastim, Abatacept - Sickle Cell Disease | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 6 | 2023-12-28 | 2026-04-29 |
| Realizing Effectiveness Across Continents With Hydroxyurea Hydroxyurea - Sickle Cell Disease, Children | Phase 2 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 811 | 2023-10-27 | 2026-04-21 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2023-06-27 | 2026-08-19 |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms Luspatercept - Myelodysplastic Syndromes, Myeloproliferative Neoplasm | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-21 | 2026-05-05 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) Oral Azacitidine, Placebo for Oral Azacitidine - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 230 | 2022-12-14 | 2026-02-25 |
Showing 20 of 65. Sign in to see all of them.
Anemia, Sickle Cell (22) · Anemia, Aplastic (11) · Myelodysplastic Syndromes (11) · Anemia, Refractory, with Excess of Blasts (10) · beta-Thalassemia (10) · Leukemia, Myeloid, Acute (7) · Graft vs Host Disease (6) · Hemoglobinuria, Paroxysmal (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Thalassemia (6) · Hodgkin Disease (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Myeloproliferative Disorders (5) · Bone Marrow Failure Disorders (4)
Hemic and Lymphatic Diseases (65) · Hematologic Diseases (63) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Anemia, Hemolytic (36) · Genetic Diseases, Inborn (35) · Bone Marrow Diseases (30) · Anemia, Hemolytic, Congenital (29) · Hemoglobinopathies (27) · Immune System Diseases (15) · Neoplasms (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Chronic Disease (12) · Disease Attributes (12)
Cyclophosphamide (12) · Sirolimus (12) · Alemtuzumab (9) · Whole-Body Irradiation (7) · Hydroxyurea (6) · Mycophenolic Acid (6) · fludarabine (6) · Cyclosporine (5) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Melphalan (5) · fludarabine phosphate (5) · Azacitidine (4) · Tacrolimus (4) · mitapivat (4)
National Heart, Lung, and Blood Institute (NHLBI) (11) · Agios Pharmaceuticals, Inc. (4) · Bristol-Myers Squibb (3) · National Cancer Institute (NCI) (3) · Children's Hospital Medical Center, Cincinnati (2) · City of Hope Medical Center (2) · Editas Medicine, Inc. (2) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Beam Therapeutics Inc. (1) · Bellicum Pharmaceuticals (1) · Beni-Suef University (1) · Bioray Laboratories (1) · Boston Children's Hospital (1) · Centre For International Health (1)
United States (44) · Canada (11) · China (10) · United Kingdom (7) · Italy (6) · Germany (5) · France (4) · Greece (4) · Angola (3) · Australia (3) · Kenya (3) · Spain (3) · Turkey (Türkiye) (3) · Belgium (2) · Brazil (2)
Courtney F Joseph, M.D. (2) · John F Tisdale, M.D. (2) · Russell Ware, MD, PhD (2) · Akshay Sharma, MBBS (1) · Alberto Piperno, MD, PhD (1) · Alexey Danilov (1) · Andre Larochelle, M.D. (1) · Ann Haight, MD (1) · Auayporn P. Nademanee, MD (1) · Bhavisha A Patel, M.D. (1) · Bhavisha Patel, M.D. (1) · Courtney D Fitzhugh, M.D. (1)
PMID 36240296, PMID 42133908, PMID 40010689, PMID 41809202, PMID 41871072, PMID 41954645, PMID 20007560, PMID 25058217, PMID 26275071, PMID 26354756, PMID 28851784, PMID 29318647, PMID 29419434, PMID 29618479, PMID 29674506, PMID 29958797, PMID 30501550, PMID 33410523, PMID 33910334, PMID 34086408, PMID 34525188, PMID 34724566, PMID 34917079, PMID 35110690, PMID 35964609, PMID 36860093, PMID 36975201, PMID 37031691, PMID 37254256, PMID 37606495, PMID 37934880, PMID 38450513, PMID 38691679, PMID 38701812, PMID 38841694, PMID 38866240, PMID 39644907, PMID 41026975, PMID 41461260, PMID 41493372, PMID 41931046, PMID 41931047, PMID 41931048, PMID 42220645, PMID 42233421, PMID 42629427, PMID 42913682
2018 (2), P30CA033572 (2), 1OT2HL154815 (1), 2023 (1), N01CM17103 (1), N01CM62204 (1), P30CA013330 (1), P30CA015704 (1), P50HL110787 (1), U01HL133883 (1), U10CA032102 (1), U10CA180888 (1), UM1CA186689 (1)